Sam Isaly, OrbiMed Advisors managing partner, says valuations are more than they used to be but adds, they're not crazy, they're sensible. He shares his view of the biotech sector.» Read More
Why the biotech space still has room to run, with John Stoltzfus, Oppeneimer, and the "Closing Bell" panel.
Biotechs and small caps are the top performers on Wall Street, with the health-care subsector up about 8 percent for the week.
As the biotech sector and names such as Biogen continue to surge, finding value is becoming increasingly difficult, an expert says.
David Seaburg, Cowen & Co., and Ari Wald, Oppenheimer, join "Power Lunch" to discuss the biotech rally.
Yaron Werber, Citi Investment Research, discusses recent Biogen activity and his investment outlook on the stock. "This stock has upside," says Werber.
CNBC's Dominic Chu reports which biotech stocks are fueling the run higher in the iShares Nasdaq Biotech ETF, the IBB.
Biologists called for a ban of a new genome-editing technique in a way that the DNA can be inherited, The New York Times reports.
CNBC's Meg Tirrell reports the biotech company got better than expected results regarding its Alzheimer's drug.
CNBC's Meg Tirrell has the latest results on the biotech's Alzheimer's drug.
A Biogen Alzheimer's drug showed a significant slowing of the disease's hallmark cognitive declines.
Celgene's phase 2 study of its experimental Crohn's disease pill was published in The New England Journal of Medicine. Phase 3 is expected to start this year, reports CNBC's Meg Tirrell.
As Biogen Idec gets set to reveal new data on its Alzheimer's drug, BIIB037, investors should be prepared for a big move either way.
Studies of a new class of cholesterol-lowering drugs signal that they can reduce by half the risk of heart attack.
Here are the stocks to watch heading out of this weekend's American College of Cardiology conference in San Diego.
Biotechs are on a tear. Akiva Felt, Oppenheimer, provides perspective on the biotech boom, and his favorite picks in the space.
A destructive insect's growing resistance to genetically modified corn seeds is costing American farmers as much as $2 billion annually.
Copycat biotech drugs in the U.S. market could cut prices of expensive medications by 40 percent to 50 percent, said a top CVS Health exec.
Acadia Pharmaceuticals fell more than 22 percent in after-hours trading Wednesday on news that its CEO is retiring.
Dr. Kathryn Schmitz, Professor of Epidemiology at University of Pennsylvania, speaks about a new app, "Share the Journey", which is said to track issues related to breast cancer treatment.
Our goal is to offer the most choice at the lowest price, says Dr. Steve Miller, Express Scripts CMO, discussing what's behind the rising costs of specialty medications and how drugmakers plan to keep costs down.
Get the best of CNBC in your inbox